@article{a1bceda51c3a4cb7bb22b8d9a89bc39f,
title = "An examination of rostral anterior cingulate cortex function and neurochemistry in obsessive-compulsive disorder",
abstract = "The anterior cingulate cortex is implicated in the neurobiology of obsessive-compulsive disorder (OCD). However, few studies have examined functional and neurochemical abnormalities specifically in the rostral subdivision of the ACC (rACC) in OCD patients. We used functional magnetic resonance imaging (fMRI) during an emotional counting Stroop task and single-voxel J-resolved proton magnetic resonance spectroscopy (1 H-MRS) in the rACC to examine the function and neurochemistry of the rACC in individuals with OCD and comparison individuals without OCD. Between-group differences in rACC activation and glutamine/glutamate ratio (Gln/Glu), Glu, and Gln levels, as well as associations between rACC activation, Gln/Glu, Glu, Gln, behavioral, and clinical measures were examined using linear regression. In a sample of 30 participants with OCD and 29 age-and sex-matched participants without OCD, participants with OCD displayed significantly reduced rACC deactivation compared with those without OCD in response to OCD-specific words versus neutral words on the emotional counting Stroop task. However, Gln/Glu, Glu, and Gln in the rACC did not differ between groups nor was there an association between reduced rACC deactivation and Gln/Glu, Glu, or Gln in the OCD group. Taken together, these findings strengthen the evidence for rACC dysfunction in OCD, but weigh against an underlying association with abnormal rACC glutamatergic neurotransmission.",
author = "Brennan, {Brian P.} and Olga Tkachenko and Schwab, {Zachary J.} and Juelich, {Richard J.} and Ryan, {Erin M.} and Athey, {Alison J.} and Pope, {Harrison G.} and Jenike, {Michael A.} and Baker, {Justin T.} and Killgore, {William Ds} and Hudson, {James I.} and Jensen, {J. Eric} and Rauch, {Scott L.}",
note = "Funding Information: Dr Brennan has received research grant support from Eli Lilly and Transcept Pharmaceuticals. Dr Hudson has received consulting fees from Genentech, HealthCore, Roche, and Shire; has received research grant support from Genentech, Otsuka, and Shire; and has received compensation for expert legal testimony from various law firms. Dr Pope has received compensation for expert legal testimony from various law firms. Over the past 3 years, Dr Rauch has received compensation from NIMH, University of North Carolina, University of Cincinnati, The Center for Addiction and Mental Health–Toronto, Oxford University Press, APPI, Elsevier Publishing, The American Psychiatric Foundation, WGBH, and Hall -Mercer (in addition to his primary employer, Partners Healthcare). The authors declare no conflict of interest. Funding Information: We thank Diane Davey, Brittany Mathes, Jordan Cattie, and Marie-Christine Andre for assistance with screening and recruitment of participants. We also thank the OCD patients who participated in this study. This work was funded in part by grant K23-MH092397 from the National Institute of Mental Health (to BPB), the Sidney R Baer, Jr Foundation through a NARSAD Young Investigator Award (to BPB), Grant K23-MH104515 from the National Institute of Mental Health (to JTB), and the David Judah Fund at Massachusetts General Hospital (to MAJ). Publisher Copyright: {\textcopyright} 2015 American College of Neuropsychopharmacology.",
year = "2015",
month = jul,
day = "13",
doi = "10.1038/npp.2015.36",
language = "English (US)",
volume = "40",
pages = "1866--1876",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "8",
}